Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. - Wikidata - awgldk - TriplyDB

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.

http://www.wikidata.org/entity/Q40672409

about

Bisphosphonates for osteoporosis in people with cystic fibrosis Bisphosphonates for osteoporosis in people with cystic fibrosis Bisphosphonates for osteoporosis in people with cystic fibrosis The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks?Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model Bisphosphonates: from bench to bedside Carpal Tunnel Syndrome Associated with Oral Bisphosphonates. A Population-Based Cohort Study The pharmacology of bisphosphonates and new insights into their mechanisms of action.Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.Acute effects of intravenous administration of pamidronate in patients with osteoporosis.Bisphosphonates pathway.A rare case of zolendronate infusion complication leading to glaucoma filtration surgery Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone Significance and impact of bisphosphonate-induced acute phase responses.Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.The Effects of Re-challenge in Patients with a History of Acute Anterior Uveitis Following Intravenous Zoledronate.Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.Effects of Artemisia Princeps Supplementation on Bone Metabolism in Ovariectomized Rats.Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion.Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate.Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin.The Author Response: Acute Effects of Intravenous Administration of Pamidronate in Patients with Osteoporosis.Drug-induced uveitis.The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.Cytokines and insulin resistance after zoledronic acid-induced acute phase response.Long-Term Effects of Amino-Bisphosphonates on Circulating γδ T Cells Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial

P2860

Q24197936-C9B2E356-EC11-46B2-B336-8CE03F34CFAC Q24200401-58749AC6-BD50-467D-B1FD-DDF9466AE252 Q24239980-75F2966A-36C7-4CC6-89E8-CABFA16E7F3D Q24684244-4D2929F8-04AF-4B9E-BBB9-34CC9F56EDED Q27024738-2F6B82BB-3892-4A56-95D9-F3E0120DB139 Q28192081-8497D4B9-EDFE-48B6-8C9D-9F264AEDCDFA Q28251212-48213EF7-C665-48E4-B919-CFD425C3D087 Q28384121-C5885FD7-91B4-4391-A537-4307FC8482D4 Q33746152-FBFF0FF4-B485-4B42-ABBD-164747EC6D69 Q33970595-7BD5D356-1199-48E3-8098-40787D0D02A9 Q34073677-E7F3AC1E-6112-4C6F-946F-C7F969783456 Q34905878-D35FA7A4-0E31-4A17-A75E-D256A365D216 Q35182568-24282ADA-9367-4F95-8C42-71A694F66284 Q35740351-97E62446-F084-4925-AB1B-AE373047E595 Q36674213-690869DB-4796-4034-9EB4-ED8BFBA3F290 Q37018333-43F6649D-E8FD-49DB-A57F-F8A2E41E0712 Q37856911-1C5563DB-9BB2-4CE0-A458-FA98201D885E Q38498607-5E59CF1E-830E-41E3-81C7-242DAD5E2962 Q38728528-A3BF4212-B345-48A5-98CF-77CBB2400F60 Q39832136-33CAD6EB-0E30-45D4-A2A8-6630F10182FD Q40310722-17F420F4-FF06-45C2-81EC-8B2CB33C4AB4 Q40617031-ACFB5E96-BF1B-440B-90D0-BCA5069876DA Q41115341-FA8AE565-D6C3-437B-A8E3-F8E45C1D75CE Q41928631-BEBB659E-2457-4223-A45B-A08C35E652C5 Q42172781-1CEAF076-D851-4129-AEF1-774F1C027BA6 Q42341488-0098E148-1BD7-4588-AA01-84621429272B Q44898932-F65A9551-26D6-405F-AFEA-75394E3F5101 Q46509055-56ED680F-DBD1-4876-9FB7-25E5F50C68CF Q51023399-07464791-905F-40F0-9BEF-2BD19B535370 Q53164170-D8B32541-151E-498D-935B-5790785D3636 Q54297545-AF940120-94EB-4AE3-9F79-251B53B40541 Q58903536-274B265E-6F30-4CCB-B5BB-BC4DBC5B9D75 Q58948155-A4872F07-1B1F-4B56-99DD-7D80CCBF046E

P2860

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.

http://www.wikidata.org/entity/Q40672409

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Interleukin-6 and tumor necros ...... d in patients with malignancy.

@en

type

label

Interleukin-6 and tumor necros ...... d in patients with malignancy.

@en

prefLabel

Interleukin-6 and tumor necros ...... d in patients with malignancy.

@en

P1433

Q40672409-15D8FC61-E32A-43B3-A855-FEBCA10FE9BB

P1476

Q40672409-4AAD9632-DC17-4C84-8764-99502A9F3049

P2093

Q40672409-18B82F3D-F9BC-4DBB-AF48-B0F56AB8F451

Q40672409-2E4D99A1-2DED-485C-8A9B-BE00AA03677D

Q40672409-399DE984-4CFF-4E47-8160-19A31137380A

Q40672409-5972F418-0E3F-4338-9C91-16AB534468AA

Q40672409-8CD0F1AD-27F2-4350-A204-9FF1C67C210D

Q40672409-A858A14F-A995-428E-AA06-D381B6755479

Q40672409-A8EF6F73-723B-4687-BC59-7E24CAC77390

Q40672409-B438DB97-4684-4F29-BBB2-702CF398C909

Q40672409-E39B9354-1803-4926-B327-B4A7FDD97EFA

Q40672409-E3CA957F-9D1E-4579-A04C-5637BE1B6CB4

P304

Q40672409-EAAA47F7-A5C0-41BB-88E7-0B058884690F

P31

Q40672409-45CC0DEE-0637-4F3A-B552-128B88CA53F3

P356

Q40672409-2421B220-856D-4B5F-AC7C-9CDE81D2B306

P433

Q40672409-F8CB6F32-8EC8-4937-BFBF-054E5CC0A0EF

P478

Q40672409-1E88795B-1E38-4FDA-A3C8-F92D86513B60

P577

Q40672409-232C3489-82E0-4961-BABC-B97961BDE55B

P698

Q40672409-67B2BDF9-98FE-4FF5-871C-2806CCC12BAE

P356

8756-3282(95)00448-3

P1433

P1476

Interleukin-6 and tumor necros ...... d in patients with malignancy.

@en

P2093

A Sauty

http://www.w3.org/2001/XMLSchema#string

D Thiebaud

http://www.w3.org/2001/XMLSchema#string

H Ludwig

http://www.w3.org/2001/XMLSchema#string

I Zimmer-Roth

http://www.w3.org/2001/XMLSchema#string

L Juillerat

http://www.w3.org/2001/XMLSchema#string

M Markert

http://www.w3.org/2001/XMLSchema#string

M Pecherstorfer

http://www.w3.org/2001/XMLSchema#string

P Burckhardt

http://www.w3.org/2001/XMLSchema#string

P Fioroni

http://www.w3.org/2001/XMLSchema#string

P Leuenberger

http://www.w3.org/2001/XMLSchema#string

P304

133-139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/8756-3282(95)00448-3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

1996-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8833207

http://www.w3.org/2001/XMLSchema#string